http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9827238-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15c89934a563c2e4b3ac3ae062456ff4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bf9de4085997cfdc29dec77aa483930 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A45C5-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H03L1-026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A45C5-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H04B1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A45C9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H03L1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H04B1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A45C5-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A45C5-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A45C9-00 |
| filingDate | 2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b8dc0e5e5b50e20d19c7a286da05e06 |
| publicationDate | 2017-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9827238-B2 |
| titleOfInvention | Drug treatment of overactive bladder |
| abstract | Provided are methods of treating an overactive bladder in a patient which include: administering a Myosin II ATPase inhibitor compound; or administering an X group and Y group substituted (3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrollo[2,3b] quinolin-4-one) compound of Formula 1 or administering an X group and Y group substituted (3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrollo[2,3b] quinolin-4-one) compound of Formula II; or administering pharmaceutically-acceptable salts, racemic mixtures, enantiomers, or prodrugs of said compounds, useful in their active form as inhibitors of Myosin II ATPase related to over-active bladder. Optionally the compounds are administered intervesicularly into the bladder. Also provided are pharmaceutical compositions comprising said compounds useful in their active form, as methods of treating a patient suffering from an over-active bladder related to inhibition of Myosin II ATPase. These pharmaceutical compositions also may contain one or more other compounds useful in their active form, as methods of treating a patient suffering from an over-active bladder. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11746112-B2 |
| priorityDate | 2011-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 538.